Advertisement

American Journal of Respiratory Medicine

, Volume 2, Issue 4, pp 287–297 | Cite as

Adverse Effects of β-Agonists

Are They Clinically Relevant?
  • Michael J. AbramsonEmail author
  • Julia Walters
  • E. Haydn Walters
Current Opinion

Abstract

Inhaled β2-adrenoceptor agonists (β2-agonists) are the most commonly used asthma medications in many Western countries. Minor adverse effects such as palpitations, tremor, headache and metabolic effects are predictable and dose related. Time series studies suggested an association between the relatively nonselective β-agonist fenoterol and asthma deaths. Three case-control studies confirmed that among patients prescribed fenoterol, the risk of death was significantly elevated even after controlling for the severity of asthma. The Saskatchewan study not only found an increased risk of death among patients dispensed fenoterol, but also suggested this might be a class effect of β2-agonists. However, in subsequent studies, the long-acting β2-agonist salmeterol was not associated with increased asthma mortality. In a case-control study blood albuterol (salbutamol) concentrations were found to be 2.5 times higher among patients who died of asthma compared with controls. It is speculated that such toxic concentrations could cause tachyarrhythmias under conditions of hypoxia and hypokalemia.

The risk of asthma exacerbations and near-fatal attacks may also be increased among patients dispensed fenoterol, but this association may be largely due to confounding by severity. Although salmeterol does not appear to increase the risk of near-fatal attacks, there is a consistent association with the use of nebulized β2-agonists. Nebulized and oral β2-agonists are also associated with an increased risk of cardiovascular death, ischemic heart disease and cardiac failure. Caution should be exercised when first prescribing a β-agonist for patients with cardiovascular disease.

A potential mechanism for adverse effects with regular use of β2-agonists is tachyphylaxis. Tachyphylaxis to the bronchodilator effects of long-acting β2-agonists can occur, but has been consistently demonstrated only for formoterol (eformoterol) a full agonist, rather than salmeterol, a partial agonist. Tachyphylaxis to protection against induced bronchospasm occurs with both full and partial β2-agonists, and probably within a matter of days at most. Underlying airway responsiveness to directly acting bronchoconstricting agents is not increased when the bronchodilator effect of the regular β2-agonist has been allowed to wear off, although there may be an increase in responsiveness to indirectly acting agents. While there has been speculation that underlying airway inflammation in asthma may be made worse by regular use of short-acting β2-agonists, in contradistinction, a number of studies have shown that long-acting β2-agonists have positive anti-inflammatory effects.

An Australian Cochrane Airways Group systematic review of the randomized, controlled trials of short-acting β-agonists found only minimal and clinically unimportant differences between regular use and use as needed. Regular short-acting treatment was better than placebo. However, a subsequent systematic review has found that regular use of long-acting β-agonists had significant advantages over regular use of short-acting β-agonists. More studies and data are needed on the regular use of β2-agonists in patients not taking inhaled corticosteroids, and in potentially vulnerable groups, such as the elderly and those with particular genotypes for the β-receptor, who might be more prone to adverse effects.

Keywords

Asthma Salmeterol Formoterol Albuterol Fenoterol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The Victorian Asthma Mortality Study was supported by the National Health & Medical Research Council of Australia. The Australian Airways Network is supported by a grant from the Commonwealth Department of Health and Aged Care. We thank Neil Pearce for permission to reproduce Fig1

References

  1. 1.
    Burney P, Chinn D, Luczynska C, et al. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). EurRespir J 1996; 9(4): 687–95Google Scholar
  2. 2.
    ISAAC. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12(2): 315–35CrossRefGoogle Scholar
  3. 3.
    Janson C, Chinn S, Jarvis D, et al. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10(8): 1795–802PubMedCrossRefGoogle Scholar
  4. 4.
    Wong CS, Pavord I, Williams J, et al. Bronchodilator, cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396–9PubMedCrossRefGoogle Scholar
  5. 5.
    Neville A, Palmer JB, Gaddie J, et al. Metabolic effects of salbutamol: comparison of aerosol and intravenous administration. BMJ 1977; 1(6058): 413–4PubMedCrossRefGoogle Scholar
  6. 6.
    Burggraaf J, Westendorp RG, in’t Veen JC, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56(7): 567–9PubMedCrossRefGoogle Scholar
  7. 7.
    Williams AJ, Weiner C, Reiff D, et al. Comparison of the effect of inhaled selective and non-selective adrenergic agonists on cardiorespiratory parameters in chronic stable asthma. Pulm Pharmacol 1994; 7(4): 235–41PubMedCrossRefGoogle Scholar
  8. 8.
    Walters E, Cockroft A, Griffiths T, et al. Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels. Thorax 1981; 36: 625–58PubMedCrossRefGoogle Scholar
  9. 9.
    Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001; 24(14): 1065–80PubMedCrossRefGoogle Scholar
  10. 10.
    Pearce N, Beasley R, Crane J, et al. End of the New Zealand asthma mortality epidemic. Lancet 1995; 345(8941): 41–4PubMedCrossRefGoogle Scholar
  11. 11.
    Suissa S, Ernst P. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic. J Clin Epidemiol 1997; 50(10): 1079–88PubMedCrossRefGoogle Scholar
  12. 12.
    Lanes SF, Birmann B, Raiford D, et al. International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970–1992. J Clin Epidemiol 1997; 50(3): 321–8PubMedCrossRefGoogle Scholar
  13. 13.
    Romano F, Recchia G, Staniscia T, et al. Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980–1994. Eur J Epidemiol 2000; 16(9): 783–7PubMedCrossRefGoogle Scholar
  14. 14.
    Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1989; I(8644): 917–22CrossRefGoogle Scholar
  15. 15.
    Crane J, Pearce N, Burgess C, et al. Asthma and the beta agonist debate. Thorax 1995; 50Suppl. 1: S5–10PubMedCrossRefGoogle Scholar
  16. 16.
    Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977–81. Thorax 1990; 45(3): 170–5PubMedCrossRefGoogle Scholar
  17. 17.
    Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–7: a further case-control study. Thorax 1991; 46(2): 105–11PubMedCrossRefGoogle Scholar
  18. 18.
    Spitzer WO, Suissa S, Ernst P, et al. The use of beta agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501–6PubMedCrossRefGoogle Scholar
  19. 19.
    Suissa S, Ernst P, Bolvin JF. A cohort analysis of excess mortality in asthma and the use of inhaled beta agonists. Am J Respir Crit Care Med 1994; 149: 604–10PubMedGoogle Scholar
  20. 20.
    Abramson M, Bailey M, Couper F, et al. Are asthma medications and management related to deaths from asthma?. Am J Respir Crit Care Med 2001; 163(1): 12–8PubMedGoogle Scholar
  21. 21.
    Rea HH, Scragg R, Jackson R, et al. A case-control study of deaths from asthma. Thorax 1986; 41(11): 833–9PubMedCrossRefGoogle Scholar
  22. 22.
    Beasley R, Burgess C, Pearce N, et al. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 1994; 24(7): 660–8PubMedCrossRefGoogle Scholar
  23. 23.
    Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996; 144(12): 1161–9PubMedCrossRefGoogle Scholar
  24. 24.
    Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268(24): 3462–4PubMedCrossRefGoogle Scholar
  25. 25.
    Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49(2): 247–50PubMedCrossRefGoogle Scholar
  26. 26.
    Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52(7): 612–7PubMedCrossRefGoogle Scholar
  27. 27.
    Campbell DA, McLennan G, Coates JR, et al. A comparison of asthma deaths and near-fatal asthma attacks in South Australia. Eur Respir J 1994; 7(3): 490–7PubMedCrossRefGoogle Scholar
  28. 28.
    Garrett JE, Lanes SF, Kolbe J, et al. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax 1996; 51(11): 1093–9PubMedCrossRefGoogle Scholar
  29. 29.
    Pearce N, Hensley MJ. Epidemiologic studies of beta agonists and asthma deaths. Epidemiol Rev 1998; 20(2): 173–86PubMedCrossRefGoogle Scholar
  30. 30.
    Van Ganse E, van der Linden PD, Leufkens HG, et al. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8(11): 1856–60PubMedCrossRefGoogle Scholar
  31. 31.
    Van der Merwe L, Plaatjes M, Van Schalwyk E, et al. Risk factors for near-fatal and fatal asthma in a third world population [abstract]. Respirology 2002; 7 Suppl.: A26Google Scholar
  32. 32.
    Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53(1): 7–13PubMedCrossRefGoogle Scholar
  33. 33.
    Suissa S, Hemmelgarn B, Biais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154(6 Pt 1): 1598–602PubMedGoogle Scholar
  34. 34.
    Martin RM, Dunn NR, Freemantle SN, et al. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 1998; 53(7): 558–62PubMedCrossRefGoogle Scholar
  35. 35.
    Au DH, Curtis JR, Psaty BM. Risk of myocardial ischaemia and beta-adrenoceptor agonists. Ann Med 2001; 33(5): 287–90PubMedCrossRefGoogle Scholar
  36. 36.
    Holgate ST, Baldwin CJ, Tattersfield AE. Beta-adrenergic agonist resistance in normal human airways. Lancet 1977; II(8034): 375–7CrossRefGoogle Scholar
  37. 37.
    Harvey JE, Baldwin CJ, Wood PJ, et al. Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. Clin Sci (Lond) 1981; 60(5): 579–85Google Scholar
  38. 38.
    Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6PubMedCrossRefGoogle Scholar
  39. 39.
    Newnham D, Grove A, McDevitt D, et al. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 475–504CrossRefGoogle Scholar
  40. 40.
    O’Connor BJ, Fuller RW, Barnes PJ. Nonbronchodilator effects of inhaled beta 2 agonists: greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1994; 150(2): 381–7PubMedGoogle Scholar
  41. 41.
    Beach JR, Young CL, Harkawat R, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155–7PubMedCrossRefGoogle Scholar
  42. 42.
    Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51: 1100–4PubMedCrossRefGoogle Scholar
  43. 43.
    Cockcroft DW, Swystun VA. Functional antagonism produced by inhaled beta agonists. Thorax 1996; 51: 1051–6PubMedCrossRefGoogle Scholar
  44. 44.
    Aldridge RE, Hancox RJ, Robin Taylor D, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000; 161(5): 1459–64PubMedGoogle Scholar
  45. 45.
    Mclvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924–30Google Scholar
  46. 46.
    Page CP. An explanation of the asthma paradox. Am Rev Resp Dis 1993; 147: S29–33PubMedGoogle Scholar
  47. 47.
    Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493–9PubMedGoogle Scholar
  48. 48.
    Walters EH, Bjermer L, Faurschou P, et al. The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients. Respir Med 2000; 94Suppl. F: S26–31PubMedCrossRefGoogle Scholar
  49. 49.
    Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159(1): 79–86PubMedGoogle Scholar
  50. 50.
    Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274(2): 1005–10PubMedCrossRefGoogle Scholar
  51. 51.
    Orsida BE, Ward C, Li X, et al. Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164(1): 117–21PubMedGoogle Scholar
  52. 52.
    Walters EH, Walters JA. A genetic twist to the beta-agonist ‘debate’. Clin Sci (Lond) 1999; 96(3): 219–20CrossRefGoogle Scholar
  53. 53.
    Walters E, Walters J. Inhaled short acting beta-2 agonist use in asthma: regular versus as-needed treatment. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Oxford Update Software, 2000; Issue 3Google Scholar
  54. 54.
    Walters EH, Walters JA, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta-agoinists in adults and children with stable asthma. Cochrane Database Syst Rev 2003; (1)Google Scholar
  55. 55.
    Wooltorton E. Salmeterol (Severent) asthma trial halted early. CMAJ 2003; 168(6): 738PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Michael J. Abramson
    • 1
    Email author
  • Julia Walters
    • 2
  • E. Haydn Walters
    • 2
  1. 1.Department of Epidemiology & Preventive MedicineMonash UniversityMelbourneAustralia
  2. 2.Department of Clinical SciencesUniversity of Tasmania Medical SchoolHobartAustralia

Personalised recommendations